Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sichuan Baili Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Sichuan Baili Pharmaceutical Co (Global / Institutional) sponsors 89 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 88 active protocols (44 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.1%
Median Closed Enrollment vs National (145 pts)73 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sichuan Baili Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)89
Active Pipeline (Recruiting Now)88 (44)
Completed vs Stopped Early0 / 1 (1.1%)
Median Closed Actual Enrollment73 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sichuan Baili Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality21
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong17
Cancer Hospital Chinese Academy of Medical SciencesBeijing10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sichuan Baili Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06891833A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-PosPhase II/IIIRECRUITING
NCT05956587A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal CarcinomaPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Sichuan Baili Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI